Assessment of AI Program 'DRISTi' as a Screening Tool
Artelus AI · NCT07222293
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 21+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 900
- US sites recruiting
- 2
- Study start
- November 23, 2025
- Record last updated
- December 9, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
A study will be conducted to demonstrate that DRISTi will correctly diagnose Diabetic Retinopathy (e.g., mtmDR, PDR, DME) in eyes of patients with diabetes. Participants who have been diagnosed with diabetes mellitus and meet the other inclusion/exclusion criteria will be invited to participate and will consent to have ophthalmic images taken. These images will be analyzed by DRISTi AI software and evaluated by an ophthalmic reading center. The results will be compared, and a statistical analysis will be completed to ensure statistical significance in the outcomes thus proving DRISTi is an effective DR diagnosis tool.
Being studied: Fundus Image Grading
Conditions: Diabetic Retinopathy (DR)
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Ability to sign and date the informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Age (≥)21 years of age or older
- Diagnosed with diabetes mellitus as per criteria established by the World Health Organization (WHO) or the American Diabetes Association (ADA)
- Hemoglobin A1c (HbA1c) ≥ 6.5%
- Fasting Plasma Glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L)
- Symptoms of hyperglycemia or hyperglycemic crisis with a random plasma glucose (RPG) ≥ 200 mg/dL (11.1 mmol/L)
Exclusion Criteria
- Persistent visual impairment in one or both eyes;
- History of macular edema or retinal vascular (vein or artery) occlusion;
- History of ocular injections, laser treatment of the retina, or intraocular surgery other than cataract surgery without complications;
- Subject is contraindicated for fundus photography (for example, has light sensitivity);
- Subject has contraindications for mydriatic medications or is unwilling or unable to dilate;
- Subject is currently enrolled in an interventional study of an investigational device or drug for the same condition; or
- Subject has a condition or is in a situation which in the opinion of the Investigator, might confound study results, may interfere significantly with the subject's participation in the study, or may result in ungradable clinical reference standard photographs
- Subject falls into one of the below categories:
- Adults unable to consent (individuals w/ impaired decision-making capacity)
- Individuals who are not yet adults (infants, children, teenagers)
- Pregnant women
- Prisoners
Recruiting US locations
New Century Ophthalmology - Oxford
Oxford, NC 27565
Site contact: Jeanne Champion, Site Coordinator Oxford · 9192347003 · Jeanne@ncophth.com
New Century Ophthalmology - Raleigh
Raleigh, NC 27617
Site contact: Adriana Valencia, Site Coordinator Raleigh · 9192347406 · Adriana@ncophth.com
Study contacts (from the official record)
- Jeanne Champion, Primary Site Coordinator Oxford · 9192347003 · Jeanne@ncophth.com
- Adriana Valencia, Site Coordinator Raleigh · 9192347406 · Adriana@ncophth.com
Similar studies in North Carolina
All diabetes studies in North Carolina →- RecruitingPhase 1Overnight stay mentioned
A Study of GNTI-122 in Adults Recently Diagnosed With T1D
GentiBio, Inc
- Location
- Chapel Hill, NC + 8 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1
Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance.
David D'Alessio, M.D.
- Location
- Durham, NC
- Eligibility basics
- Ages 18–60
- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Charlotte, NC + 55 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 3
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
Merck Sharp & Dohme LLC
- Location
- Wake Forest, NC + 27 other US sites
- Eligibility basics
- Ages 18+